Bayer Phase IV study met its primary endpoint in PAH patients who had transitioned to Adempas® (riociguat) after insufficient response to PDE5 inhibitors
Data presented as a late-breaker during a virtual ALERT session at the annual meeting of the European Respiratory Society Outcomes from the randomized, controlled, open-label REPLACE study included results from 226 patients with pulmonary arterial hypertension (PAH) WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced